- Home
- KPLT vs ATOS Comparison
KPLT vs ATOS Comparison
Compare KPLT & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- ATOS
- Stock Information
- Founded
- KPLT 2012
- ATOS 2009
- Country
- KPLT United States
- ATOS United States
- Employees
- KPLT N/A
- ATOS N/A
- Industry
- KPLT Diversified Commercial Services
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- ATOS Health Care
- Exchange
- KPLT Nasdaq
- ATOS Nasdaq
- Market Cap
- KPLT 97.4M
- ATOS 107.2M
- IPO Year
- KPLT N/A
- ATOS 2012
- Fundamental
- Price
- KPLT $20.00
- ATOS $0.87
- Analyst Decision
- KPLT Hold
- ATOS Strong Buy
- Analyst Count
- KPLT 1
- ATOS 3
- Target Price
- KPLT $10.00
- ATOS $6.17
- AVG Volume (30 Days)
- KPLT 102.6K
- ATOS 459.7K
- Earning Date
- KPLT 11-05-2025
- ATOS 11-11-2025
- Dividend Yield
- KPLT N/A
- ATOS N/A
- EPS Growth
- KPLT N/A
- ATOS N/A
- EPS
- KPLT N/A
- ATOS N/A
- Revenue
- KPLT $267,101,999.00
- ATOS N/A
- Revenue This Year
- KPLT $22.88
- ATOS N/A
- Revenue Next Year
- KPLT $10.98
- ATOS N/A
- P/E Ratio
- KPLT N/A
- ATOS N/A
- Revenue Growth
- KPLT 13.04
- ATOS N/A
- 52 Week Low
- KPLT $5.08
- ATOS $0.55
- 52 Week High
- KPLT $24.34
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- KPLT 56.54
- ATOS 64.43
- Support Level
- KPLT $18.37
- ATOS $0.81
- Resistance Level
- KPLT $23.07
- ATOS $0.85
- Average True Range (ATR)
- KPLT 2.57
- ATOS 0.03
- MACD
- KPLT -0.12
- ATOS 0.01
- Stochastic Oscillator
- KPLT 60.47
- ATOS 98.39
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.